Vericel Corporation (VCEL) Earnings
Vericel Corporation is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $-0.04. VCEL has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +173.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.15 | $-0.12 | +20.0% | $68M | +7.5% |
| Feb 26, 2026 | $0.45 | $0.45 | -0.8% | $93M | +0.3% |
| Nov 6, 2025 | $-0.02 | $0.10 | +600.0% | $68M | -27.2% |
| Jul 31, 2025 | $-0.04 | $-0.01 | +75.0% | $63M | -2.1% |
| May 8, 2025 | $-0.09 | $-0.23 | -155.6% | $53M | -18.8% |
| Feb 27, 2025 | $0.31 | $0.38 | +22.6% | $75M | +29.7% |
| Nov 7, 2024 | $-0.05 | $-0.02 | +60.0% | $58M | -25.7% |
| Aug 1, 2024 | $-0.10 | $-0.10 | +0.0% | $53M | -4.6% |
| Feb 29, 2024 | $0.17 | $0.26 | +52.9% | $65M | +1.7% |
| Aug 2, 2023 | $-0.13 | $-0.11 | +15.4% | $46M | +2.1% |
| Feb 23, 2023 | $0.04 | $0.12 | +239.0% | $53M | -0.4% |
| Aug 3, 2022 | $-0.13 | $-0.19 | -46.2% | $37M | -3.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Nick Colangelo mentioned the company had great first quarter with strong financial and commercial results. Macy had double-digit volume growth, expanded sales force in new territories with strong performance in biopsies, implants, etc. Burn care had strong revenue growth and announced BARDA award. Joe Marra discussed financial measures, margin expansion, and updated revenue guidance. Focus on Macy's commercial excellence initiatives, Macy-Arthro leading indicators, and progress on clinical data for Macy-Arthro. Also, progress on FDA approval for Macy commercial manufacturing and plans for UK marketing application.
Guidance
Raised total revenue guidance range by $10 million to $326 - $336 million. Raised Macy revenue guidance to $282 - $288 million, expecting ~$62.5 - $63.5 million in Q2. Raised burn care revenue guidance to ~$44 - $48 million, expecting ~$9 - $10 million in Q2. Expect ~$5 - $6 million of Nexabrid BARDA procurement revenue in second half, with procurement starting in Q3. Continue to expect gross margin ~75% and adjusted EBITDA margin ~27% for full year, ~72% gross margin and ~18% adjusted EBITDA margin for Q2.
Segment performance
Total revenue was over $68 million, up 30% year-over-year. Macy had record first quarter revenue of over $56 million, a 22% increase vs prior year, with double-digit volume growth. Burn care first quarter revenue increased over 90% to $12 million. Macy's trailing four-quarter revenue growth rate was 23%, Burn care's trailing four-quarter growth rate was above 20%. Gross margin increased over 300 basis points to 72%, adjusted EBITDA margin increased nearly 800 basis points to 14%, adjusted EBITDA tripled to nearly $10 million. Free cash flow was over $15 million, ending the quarter with over $210 million in cash and investments.
Analyst Q&A
Q: On guidance outlook, what's the assumption set for Macy Trends and Arthro moving through the year and in Q2.
A: Joe Marra discussed drivers of guidance increase including Q1 outperformance and Nexabrid barter revenue. Assumptions on burn care and Macy's execution.